Long QT Syndrome Type 5-Lite: Defining the Clinical Phenotype Associated with the Potentially Proarrhythmic P.Asp85Asn-KCNE1 Common Genetic Variant
Overview
Authors
Affiliations
Background: Long QT syndrome (LQTS) genetic test reports commonly exclude potentially proarrhythmic common variants such as p.Asp85Asn-KCNE1.
Objective: The purpose of this study was to determine whether a discernible phenotype is associated with p.Asp85Asn-KCNE1 and whether relatively common KCNE1 variants underlie transient QT prolongation pedigrees with negative commercial LQTS genetic tests.
Methods: Retrospective review was used to compare demographics, symptomatology, and QT parameters of individuals with p.Asp85Asn-KCNE1 in the absence of other rare/ultra-rare variants in LQTS-susceptibility genes and those who underwent comprehensive LQTS genetic testing.
Results: Compared to the Genome Aggregation Database, p.Asp85Asn-KCNE1 was more prevalent in individuals undergoing LQTS genetic testing (33/1248 [2.6%] vs 1552/126,652 [1.2%]; P = .0001). In 19 of 33 patients (58%), only p.Asp85Asn-KCNE1 was observed. These patients were predominantly female (90% vs 62%; P = .01) and were less likely to experience syncope (0% vs 34%; P = .0007), receive β-blockers (53% vs 85%; P = .001), or require an implantable cardioverter-defibrillator (5.3% vs 33%; P = .01). However, they exhibited a similar degree of QT prolongation (QTc 460 ms vs 467 ms; P = NS). Whole exome sequencing of 2 commercially genotype-negative pedigrees revealed that p.Asp85Asn-KCNE1 and p.Arg36His-KCNE1 traced with a transient QT prolongation phenotype. Functional characterization of p.Arg36His-KCNE1 demonstrated loss of function, with a 47% reduction in peak I current density in the heterozygous state.
Conclusion: We provide further evidence that relatively common variants in KCNE1 may result in a mild QT phenotype designated as "LQT5-Lite" to distinguish such potentially proarrhythmic common variants (ie, functional risk alleles) from rare pathogenic variants that truly confer monogenic disease susceptibility, albeit with incomplete penetrance.
Multisite Validation of a Functional Assay to Adjudicate Brugada Syndrome-Associated Variants.
Ma J, ONeill M, Richardson E, Thomson K, Ingles J, Muhammad A Circ Genom Precis Med. 2024; 17(4):e004569.
PMID: 38953211 PMC: 11335442. DOI: 10.1161/CIRCGEN.124.004569.
Multi-site validation of a functional assay to adjudicate Brugada Syndrome-associated variants.
Ma J, ONeill M, Richardson E, Thomson K, Ingles J, Muhammad A medRxiv. 2024; .
PMID: 38196587 PMC: 10775332. DOI: 10.1101/2023.12.19.23299592.
Votypka P, Krebsova A, Norambuena-Poustkova P, Peldova P, Kucerova S, Kulvajtova M Int J Legal Med. 2023; 137(6):1787-1801.
PMID: 37178278 PMC: 10567875. DOI: 10.1007/s00414-023-03007-z.
ONeill M, Sala L, Denjoy I, Wada Y, Kozek K, Crotti L Genet Med. 2022; 25(3):100355.
PMID: 36496179 PMC: 9992222. DOI: 10.1016/j.gim.2022.12.002.
Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare Variants.
Kozek K, Wada Y, Sala L, Denjoy I, Egly C, ONeill M Circ Genom Precis Med. 2021; 14(4):e003289.
PMID: 34309407 PMC: 8373797. DOI: 10.1161/CIRCGEN.120.003289.